Teva Health Systems (Irvine, CA), part of Teva Pharmaceuticals, recently announced the introduction and availability of Epirubicin Hydrochloride Injection. This product is AP-rated to Ellence Injection (Pharmacia & Upjohn). Epirubicin Hydrochloride Injection is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer. This product is administered to patients by intravenous infusion. It is given in repeated 3- to 4-week cycles. The total dose of Epirubicin Hydrochloride Injection may be given on Day 1 of each cycle or divided equally and given on Days 1 and 8 of each cycle. Epirubicin Hydrochloride Injection is available in 2 mg/mL, 50 mg and 2 mg/mL, 200 mg in single-dose polymer vials. For more information, visit www.tevausa.com, or call 888-TEVA-USA (888-838-2872).
Tercica Inc (Brisbane, CA) recently received FDA approval to market Somatuline Depot Injection 60, 90, and 120 mg/mL in the United States. This product is indicated for the long-term treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option. Patients should begin treatment with Somatuline Depot Injection 90 mg given via deep subcutaneous route every 4 weeks for 3 months. Thereafter, the dose should be adjusted according to the response of the patient as judged by a reduction in serum growth hormone and/or insulin-like growth factor I levels; and/or changes in symptoms of acromegaly. The starting dose in patients with moderate and severe renal or moderate and severe hepatic impairment should be 60 mg via deep subcutaneous route every 4 weeks for 3 months. The product is available in 60-, 90-, and 120-mg sterile, single-use, prefilled syringes. The prefilled syringes contain a white to pale yellow, semisolid formulation. For more information, call 866-837-2422, or visit www.somatulinedepot.com.
TopoTarget USA Inc (Rockaway, NJ), the US subsidiary of TopoTarget A/S, recently announced that Totect is now available to cancer treatment facilities throughout the United States through its distributor ASD Healthcare and Oncology Supply. Totect is the only FDA-approved treatment for extravasation from intravenous anthracycline chemotherapy, the accidental leakage of chemotherapy drugs into surrounding tissue. The company received FDA approval, under an orphan drug designation, on September 6, 2007.Totect should be given once daily for 3 consecutive days. The first infusion should be initiated as soon as possible and within the first 6 hours after extravasation. The recommended dose is 1000 mg/m2on Day 1, 1000 mg/m2on Day 2, and 500 mg/m2on Day 3. The Totect dose should be reduced by 50% in patients with creatinine clearance values <40 mL/min. This product is available as 500 mg dexrazoxane in a single-use vial that is packaged in a carton consisting of 10 vials of dexrazoxane for injection and 10 vials of diluent. For more information, visit www.totect.com, or call 866-914-2922.
Sagent Pharmaceuticals Inc (Schaumburg, IL) recently launched a full line of prefilled, ready-to-use 6-mg and 12-mg Adenosine Syringes. Adenosine injection, USP, is the generic equivalent of Astellas Pharma US Inc's Adenocard, an antiarrhythmic commonly used in the treatment of paroxysmal supraventricular tachycardia, a rhythm disturbance of the heart in critical-care situations. Adenosine works by slowing the electrical conduction in the heart, slowing heart rate of normalizing heart rhythm. The most common adverse effects may include facial flushing, shortness of breath, and chest pressure. These are generally self-limiting and resolve within a few seconds. Less common adverse effects include transient or prolonged asystole, premature ventricular contractions, and bradycardia. For more information, visit www.sagentpharma.com, or call 866-625-1618.